ALB Albemarle Corporation

Q3 2025 10-Q

Filed: Nov 5, 2025Period ending Sep 30, 2025

Health Care

Plastic Materials, Synth Resins & Nonvulcan ElastomersSEC EDGAR

Albemarle Corporation (ALB) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Revenue $1.31B Q3 2025, down 3% YoY from $1.35B Q3 2024, driven by $131.7M lower lithium pricing offset by $75.7M higher volume
• Operating (gross) margin 9.0% Q3 2025 vs loss margin (7.7%) Q3 2024, due to lower input costs and higher volume

+3 more insights

Risk Factors

• New risk: Goodwill impairment $181.1M on Refining Solutions triggered by planned divestiture agreements signed Oct 2025, indicating fair value below carrying value
• Updated operational risk: Restructuring related to Kemerton plants and Chengdu conversion led to $5.8M charges in YTD 2025 versus $1.2B in full 2024; reflects ongoing cost optimization

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$1.3B

▼ -3.5% YoY▼ -1.7% QoQ

Net Income

-$161M

▲ +85.0% YoY▼ -801.8% QoQ

Gross Margin

9.0%

▼ -581bp QoQ

Operating Margin

-16.6%

▲ +6526bp YoY▼ -2016bp QoQ

Net Margin

-12.3%

▲ +6662bp YoY▼ -1401bp QoQ

ROE

-1.6%

Total Assets

$17.1B

EPS (Diluted)

$-1.72

▲ +81.8% YoY▼ -975.0% QoQ

Operating Cash Flow

$356M

▲ +47.8% YoY▲ +5036.9% QoQ

Source: XBRL data from Albemarle Corporation Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Albemarle Corporation Quarterly Reports

Q2 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Albemarle Corporation

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.